

#6

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-001210US

U S Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On June 19, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Jana Kane

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HITOSHI *et al.*

Application No.: 10/026,021

Filed: December 21, 2001

For: SAK: MODULATION OF
CELLULAR PROLIFERATION FOR
TREATMENT OF CANCER

Examiner: Not yet assigned

Art Unit: 1646

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Nonprovisional Application mailed January 30, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

HITOSHI *et al.*
Application No.: 10/026,021
Page 3

PATENT

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
ASP:dmw

HITOSHI *et al.*
Application No.: 10/026,021
Page 4



PATENT

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 17 of page 4 has been amended as follows:

Figure 2 provides an alignment of the SAK kinase domain (SEQ ID NO:3) with other mitotic kinases (SEQ ID NOS:4-7).

Paragraph beginning at line 8 of page 39 has been amended as follows:

Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly Gly ~~gly~~ sequences of between about 5 and 200 amino acids (SEQ ID NO:8). Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Alabama. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.




I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence

Assistant Commissioner for Patents,
Washington, D C. 20231, on June 19, 2002

TOWNSEND and TOWNSEND and CREW LLP

By


Dana Kane

PATENT

Attorney Docket No.: 021044-
001210US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HITOSHI et al.

Serial No.: 10/026,021

Filed: December 21, 2002

For: SAK: MODULATION OF CELLULAR
PROLIFERATION FOR TREATMENT
OF CANCER

Examiner: Unassigned

Art Unit: 1646

LETTER TO OFFICIAL DRAFTSPERSON

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Pursuant to the Notice to File Missing Parts of Nonprovisional Application,
applicants submit 20 sheets of formal drawings to be made of record in the above-identified case,

HITOSHI et al.
Serial No.: 10/026,021
Page 2

in compliance with 37 CFR 1.84.

Respectfully submitted,



Annette S. Parent
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
(415) 576-0200
Fax (415) 576-0300
ASP:dkSF 151764 v1
SF 1357808 v1